A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma

详细信息    查看全文

• 作者：Xiaozhou Yu (1) (2) (3)
  Hua Zhao (1) (2) (3)
  Liang Liu (1) (2) (3)
  Shui Cao (1) (2) (3)
  Baozhu Ren (1) (2) (3)
  Naining Zhang (1) (2) (3)
  Xiumei An (1) (2) (3)
  Jinpu Yu (1) (2) (3)
  Hui Li (1) (2) (3)
  Xiubao Ren (1) (2) (3)
  
• 关键词：Cytokine ; induced killer cells ; hepatocellular carcinoma ; immunotherapy ; trans ; arterial chemoembolization
• 刊名：Journal of Clinical Immunology
• 出版年：2014
• 出版时间：February 2014
• 年：2014
• 卷：34
• 期：2
• 页码：194-203
• 全文大小：415 KB
• 参考文献：1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-5. doi:10.1055/s-2007-1007117 . CrossRef
  2. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother. 2002;51(8):440-. doi:10.1007/s00262-002-0298-y .
  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-0. doi:10.1056/NEJM199903113401001 . CrossRef
  4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;350(9085):1142-. doi:10.1016/S0140-6736(05)63789-0 . CrossRef
  5. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49(1):33-4. CrossRef
  6. Qiang L, Huikai L, Butt K, Wang PP, Hao X. Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma. World J Surg. 2006;30(3):439-5. doi:10.1007/s00268-005-0608-6 . CrossRef
  7. Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17(5):1226-3. doi:10.1245/s10434-010-0978-3 . CrossRef
  8. Truty MJ, Vauthey JN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010;17(5):1219-5. doi:10.1245/s10434-010-0976-5 . CrossRef
  9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421-0. CrossRef
  10. Livraghi T. Guidelines for treatment of liver cancer. Eur J Ultrasound. 2001;13(2):167-6. CrossRef
  11. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221(3):291-. CrossRef
  12. Ikai I, Itai Y, Okita K, Omata M, Kojiro M, Kobayashi K, et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004;28(1):21-. CrossRef
  13. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32(6):1224-. doi:10.1053/jhep.2000.20456 . CrossRef
  14. Fried MW. Treatment of hepatocellular carcinoma: medical options. Liver Transpl Surg. 1998;4(5 Suppl 1):S92-.
  15. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353(9160):1253-. doi:10.1016/S0140-6736(98)09148-X . CrossRef
  16. Ribero D, Curley SA, Imamura H, Madoff DC, Nagorney DM, Ng KK, et al. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol. 2008;15(4):986-2. doi:10.1245/s10434-007-9731-y . CrossRef
  17. Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240(1):102-. CrossRef
  18. Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008;26(36):5845-. doi:10.1200/JCO.2008.19.7996 . CrossRef
  19. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-11. doi:10.1093/jnci/djn134 . CrossRef
  20. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist. 2007;12(12):1425-2. doi:10.1634/theoncologist.12-12-1425 . CrossRef
  21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-0. doi:10.1056/NEJMoa0708857 . CrossRef
  22. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-4. doi:10.1016/S1470-2045(08)70285-7 . CrossRef
  23. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293-00. doi:10.1200/JCO.2005.01.3441 . CrossRef
  24. Abou-Alfa GK. Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Netw. 2009;7(4):397-03.
  25. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985;75(4):595-03.
  26. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318-1. CrossRef
  27. Yun YS, Hargrove ME, Ting CC. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res. 1989;49(17):4770-.
  28. Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012. doi:10.1007/s00262-012-1260-2 .
  29. Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol. 2010;16(48):6155-2. CrossRef
  30. Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009;41(1):36-1. doi:10.1016/j.dld.2008.04.007 . CrossRef
  31. Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18(6):1751-. doi:10.1158/1078-0432.CCR-11-2442 . CrossRef
  32. Deng Q, Bai X, Xiao X, Jiang Y, Li YM. Reversion of multidrug resistance by CIK in K562/ADR cells and its mechanism exploration. Zhonghua Xue Ye Xue Za Zhi. 2011;32(1):52-.
  33. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21(13):1673-.
  34. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41(4):707-6. doi:10.1002/hep.20636 . CrossRef
  35. Ren X, Yu J, Liu H, Zhang P, An X, Zhang N, et al. Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother Radiopharm. 2006;21(1):22-3. doi:10.1089/cbr.2006.21.22 . CrossRef
  36. Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009;11(8):1076-3. doi:10.3109/14653240903121252 . CrossRef
  37. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001;37(1):1-. doi:10.1002/mpo.1154 . CrossRef
  38. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139-9. CrossRef
  39. Shi Y, Yu J, Cen X, Zhu P, Ma M. Large-capacity expanded cytoline-induced killer cells and its cytotoxic activity. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2001;18(1):94-.
  40. Shablak A, Hawkins RE, Rothwell DG, Elkord E. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res. 2009;15(21):6503-0. doi:10.1158/1078-0432.CCR-09-1605 . CrossRef
  41. Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer. 2009;65(1):1-. doi:10.1016/j.lungcan.2008.10.018 . CrossRef
  42. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823-1. CrossRef
  43. Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer. 1986;37(6):803-1. CrossRef
  44. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 2005;175(12):7819-8.
  45. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103(8):3065-2. doi:10.1182/blood-2003-06-2125 2003-06-2125 . CrossRef
  46. Sun S, Li XM, Li XD, Yang WS. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm. 2005;20(2):173-0. doi:10.1089/cbr.2005.20.173 . CrossRef
  47. Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin Oncol. 2000;27(2):221-3.
  48. Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112(6):2563-4. doi:10.1182/blood-2007-06-092817 . CrossRef
  49. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311(5768):1780-. doi:10.1126/science.1121411 . CrossRef
  50. Lu PH, Negrin RS. A novel population of expanded human CD3-?CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153(4):1687-6.
  51. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137(2):305-0. doi:10.1007/s00432-010-0887-7 . CrossRef
  52. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356(9232):802-. doi:10.1016/S0140-6736(00)02654-4 . CrossRef
  
• 作者单位：Xiaozhou Yu (1) (2) (3)
  Hua Zhao (1) (2) (3)
  Liang Liu (1) (2) (3)
  Shui Cao (1) (2) (3)
  Baozhu Ren (1) (2) (3)
  Naining Zhang (1) (2) (3)
  Xiumei An (1) (2) (3)
  Jinpu Yu (1) (2) (3)
  Hui Li (1) (2) (3)
  Xiubao Ren (1) (2) (3)
  
  1. Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
  2. National Clinical Research Center of Cancer, Tianjin, China
  3. Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
  
• ISSN：1573-2592

文摘

Purpose This prospective study aims to explore the benefit of cytokine-induced killer cell (CIK) treatment in hepatocellular carcinoma patients, which has not yet been thoroughly studied before. Methods From January 2004 to May 2009, 132 patients who were initially diagnosed with hepatocellular carcinoma of Barcelona Clinic Liver Cancer (BCLC) stage A, B or C, Child–Pugh scores of A or B and without prior treatment were enrolled in the study. Patients were randomly assigned to either arm 1 (n--6) to receive CIK treatment plus standard treatment, or arm 2 (n--6) to receive standard treatment only. The primary end point was overall survival (OS) and the secondary endpoint was progression-free survival as evaluated by Kaplan–Meier analyses and treatment hazard ratios with the Cox proportional hazards model. Results The 1-year (OS: 74.2?% vs. 50.0?%, 95?% CI: 63.6-4.8?% vs. 37.8-2.2, p--.002), 2-year (OS: 53.0?% vs. 30.3?%, 95?% CI: 40.8-5.2?% vs. 19.1-1.5?%, p--.002), 3-year (OS: 42.4?% vs. 24.2?%, 95?% CI: 30.4-4.4?% vs. 13.8-4.6?%, p--.005) and median overall and progression-free survivals of arm 1 patients were significantly higher than those of arm 2. Therefore, in patients who are not suitable for surgery, significant benefit is obtained from CIK treatment. The main adverse effects of CIK included fever, allergy and headache pain. Conclusions Hepatocellular carcinoma patients who were not suitable for surgery demonstrate prolonged overall and progression-free survival from CIK treatment.